|
Cancer
Research |
|
|
|
Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL
Antiproliferative
effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on
tumor-derived endothelial cells
Endocrinology.
2002 Jul;143(7):2508-14 (PDF Full Text)
|
|
Bollag W
Experimental
basis of cancer combination chemotherapy with retinoids, cytokines,
1,25-dihydroxyvitamin D3, and analogs
J Cell Biochem. 1994 Dec;56(4):427-35
|
|
|
D. Michal
Freedman, Anne C. Looker, Shih-Chen Chang, and Barry I. Graubard
Prospective Study of Serum Vitamin D and Cancer Mortality in
the United States
Journal of the National Cancer Institute Advance Access published on
October 30, 2007
J. Natl. Cancer Inst. 2007 99: 1594-1602; doi:10.1093/jnci/djm204
Abstract
|
|
Majewski
S, Skopinska M, Marczak M, Szmurlo A, Bollag W, Jablonska S
Vitamin D3 is a potent inhibitor of tumor
cell-induced angiogenesis
J Investig
Dermatol Symp Proc 1996 Apr;1(1):97-101
|
|
van den
Bemd GJ, Chang GT
Vitamin
D and vitamin D analogs in cancer treatment
Curr Drug Targets. 2002 Feb;3(1):85-94
|
|
Vieth
R
Vitamin
D supplementation, 25-hydroxyvitamin D concentrations, and safety
Am J Clin Nutr 1999 May;69(5):842-56 (PDF Full Text)
|
|
Vieth
R, Chan PC, MacFarlane GD
Efficacy
and safety of vitamin D3 intake exceeding the lowest observed adverse effect
level
Am J Clin Nutr
2001 Feb;73(2):288-94 (PDF Full Text)
|
|
|
Glioblastoma |
|
|
|
Trouillas P,
Honnorat J, Bret P, Jouvet A, Gerard JP
Redifferentiation
therapy in brain tumors: long-lasting complete regression of glioblastomas and
an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol
J Neurooncol 2001 Jan;51(1):57-66
|
|
|
Neuroblastoma |
|
|
|
|
van Ginkel PR, Yang W, Marcet MM, Chow CC,
Kulkarni AD, Darjatmoko S, Lindstrom MJ, Lokken J, Bhattacharya S, Albert DM
1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma
J Neurooncol.
2007 Dec;85(3):255-62.
Epub 2007 Jun 30
Abstract |
 Reprint |
DBLinks | BL 7:6
|
|
|
Non-Nervous
System Tumors |
|
|
|
Chen
TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF
The
in vitro evaluation of 25-hydroxyvitamin D3 and
19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate
cancer
Clin Cancer Res. 2000 Mar;6(3):901-8 (PDF Full Text)
|
|
Danilenko
M, Wang Q, Wang X, Levy J, Sharoni Y, Studzinski GP
Carnosic
acid potentiates the antioxidant and prodifferentiation effects of
1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote
elevation of basal levels of intracellular calcium
Cancer Res. 2003 Mar 15;63(6):1325-32
|
|
Kumagai
T, O'Kelly J, Said JW, Koeffler HP
Vitamin
D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia,
myeloma, and colon cancer cells
J Natl
Cancer Inst. 2003 Jun 18;95(12):896-905
|
|
Molnar
I, Kute T, Willingham MC, Powell BL, Dodge WH, Schwartz GG
19-nor-1alpha,25-dihydroxyvitamin
D(2) (paricalcitol): effects on clonal proliferation, differentiation,
and apoptosis in human leukemic cell lines
J Cancer Res Clin
Oncol. 2003 Jan;129(1):35-42. Epub 2003 Feb 12
|
|
Zheng
X, Chang RL, Cui XX, Kelly KA, Shih WJ, Lin Y, Strair R, Suh J, Han ZT,
Rabson A, Conney AH
Synergistic
effects of clinically achievable concentrations of
12-O-tetradecanoylphorbol-13-acetate in combination with all-trans retinoic
acid, 1alpha,25-dihydroxyvitamin D3, and sodium butyrate on differentiation in
HL-60 cells
Oncol Res 2000;12(9-10):419-27
|
|
|
Treatment-Related
Pathology |
|
|
|
|
Ruth Lagman
and Declan Walsh
Dangerous
nutrition? Calcium, vitamin D, and shark cartilage nutritional
supplements and cancer-related hypercalcemia
Supportive Care in Cancer, DOI 10.1007/s00520-002-0428-2
Published
online:
15 January 2003
|
|
